Related Experiment Videos
Oligodeoxynucleotide-based therapeutics for human leukemias
1Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104.
Stem Cells (Dayton, Ohio)
|October 1, 1993
Summary
Antisense gene strategies targeting c-myb and c-kit show promise for treating human leukemia. Oligodeoxynucleotides can disrupt critical genes, leading to preferential leukemic cell death in ex vivo and in vivo models.
Area of Science:
- Hematopoietic cell development
- Molecular biology of cancer
- Gene regulation in leukemia
Background:
- Understanding cell and molecular biology of hematopoietic development reveals critical gene roles.
- Certain genes are key regulators of cell proliferation and growth, making them therapeutic targets.
- Targeting critical genes aims to disrupt leukemic cell function and induce cell death.
Purpose of the Study:
- To investigate the potential of antisense gene strategies for treating human leukemia.
- To evaluate the efficacy of targeting c-myb and c-kit proto-oncogenes in leukemic cells.
- To explore the use of oligodeoxynucleotides for gene disruption in hematopoietic malignancies.
Main Methods:
- Utilizing antisense gene strategies for targeted gene disruption.
- Employing oligodeoxynucleotides to perturb c-myb and c-kit proto-oncogenes.
- Applying these methods to human leukemic cells ex vivo and potentially in vivo.
Main Results:
- Demonstrated the ability of antisense technology to specifically target proto-oncogenes.
- Showed successful disruption of c-myb and c-kit gene function in leukemic cells.
- Indicated preferential leukemic cell death following gene function perturbation.
Conclusions:
- Antisense gene strategies, particularly using oligodeoxynucleotides, are a viable approach for leukemia treatment.
- Targeted gene disruption holds potential for both ex vivo and in vivo therapeutic applications.
- Further research into gene-based therapies for hematopoietic malignancies is warranted.